HB2874 amends the Illinois Controlled Substances Act’s ephedrine provisions. The bill narrows and clarifies which ephedrine-containing products are exempt from controlled-substance restrictions, focusing on over-the-counter drug products that meet federal labeling and marketing requirements, are manufactured and distributed for legitimate medicinal use, and are not promoted for stimulation, mental alertness, weight loss, appetite control, muscle enhancement, or energy. It also expressly allows certain solid oral dosage forms packaged in blister packs of no more than two tablets per blister and anorectal preparations containing no more than 5% ephedrine.
The bill also prohibits the marketing, advertising, or labeling of ephedrine products for the listed stimulant or weight-loss purposes and gives the Department authority to consider packaging, labeling, distribution, promotion, verbal claims, and the extent of misuse when assessing compliance. Violations are punishable as a Class A misdemeanor, with a second or subsequent violation elevated to a Class 4 felony. The measure preserves exclusions for certain dietary supplements, herbs, natural products, and prescription-dispensed products, and it states that it does not limit the Methamphetamine Precursor Control Act.
Impact
HB2874 updates Section 216 of the Illinois Controlled Substances Act, refining the legal treatment of ephedrine and ephedrine-containing products. It affects manufacturers, distributors, retailers, pharmacies, practitioners, and consumers by tightening the conditions under which such products may be sold without triggering controlled-substance penalties, while preserving lawful prescription and certain natural-product exceptions. The bill also reinforces state enforcement authority over product marketing and labeling tied to misuse and diversion concerns.
Sentiment
The available voting history shows strong bipartisan support and no recorded opposition: the bill passed the Illinois House 116-0 and later passed a Senate motion 57-0. No committee transcript is available, but the unanimous votes suggest broad agreement that the measure is a targeted regulatory update rather than a controversial policy change.
Contention
No explicit contention appears in the available record. The main policy tension inherent in the bill is between allowing legitimate over-the-counter and prescription access to ephedrine products and preventing their misuse for stimulation, weight loss, or methamphetamine precursor purposes. Any concerns would likely center on how strictly the Department interprets marketing, packaging, and product-use factors, but no specific objections are documented in the provided materials.